Table 2.

Interindividual variation in IFN-γ production by PBMC in response to peptides of ESAT-6 and CFP-10

Peptide(s)aNCbTB1TB2TB3TB4TB5TB6TB7
rESAT-6c+++++++++++++++++++++
ESAT-6 pmix9++++++++++++++++
p1++++++++++++
p2+++++++++
p3++++++++
p4+++++++++
p5NDd++++++++
p6+++++++++
p7++++++++++++++
p8++++++++
p9+++++++++
rCFP-10+++++++++++++++++++
CFP-10 pmix9+++++++++++++++++++
p1++++
p2++++
p3+++++++
p4+++++++
p5++++++++++++
p6++++++++++++
p7+++++
p8+++++++++++++++
p9++++++++++
  • a pmix9 denotes the mixture of nine overlapping peptides. p1 to p9 denote peptides 1 to 9.

  • b NC denotes a PPD skin test-negative, non-BCG-vaccinated control subject. TB1 through TB7 indicate TB patients with different HLA-DR phenotypes (TB1, DR4,17; TB2, DR1,15; TB3, DR4,7; TB4, DR13,15; TB5, DR15; TB6, DR11,13; TB7, DR4,13).

  • c IFN-γ production is expressed semiquantitatively as follows: −, IFN-γ level of <100 pg/ml; +, level between 100 and 300 pg/ml; ++, level between 300 and 1,000 pg/ml; +++, level of >1,000 pg/ml.

  • d ND, not determined.